Nearly 10% of the Globe to Receive Sputnik V

Reading Time: < 1 minute

Developed by state-owned Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V coronavirus vaccine was the first to pass trials and it has one of the best safety and efficacy records among the group of 5 or 6 available to the global community.

According to Telesur:

Russia has already signed contracts with 15 companies from ten nations to produce around 1.4 billion doses, which would immunize 700 million people.

Share This Post

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Have your say!